Nyxoah SA (NASDAQ:NYXH - Get Free Report) was the recipient of a significant growth in short interest during the month of May. As of May 31st, there was short interest totalling 177,800 shares, a growth of 45.5% from the May 15th total of 122,200 shares. Approximately 1.0% of the company's stock are short sold. Based on an average daily trading volume, of 167,200 shares, the days-to-cover ratio is currently 1.1 days.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. LPL Financial LLC bought a new position in Nyxoah during the fourth quarter worth about $102,000. Walleye Capital LLC raised its holdings in Nyxoah by 23.9% during the 4th quarter. Walleye Capital LLC now owns 14,831 shares of the company's stock valued at $119,000 after acquiring an additional 2,862 shares during the period. Ameriprise Financial Inc. purchased a new stake in shares of Nyxoah during the fourth quarter worth $135,000. Geode Capital Management LLC lifted its position in shares of Nyxoah by 19.4% during the fourth quarter. Geode Capital Management LLC now owns 17,100 shares of the company's stock worth $137,000 after acquiring an additional 2,774 shares in the last quarter. Finally, Kovack Advisors Inc. boosted its holdings in shares of Nyxoah by 100.0% in the fourth quarter. Kovack Advisors Inc. now owns 20,000 shares of the company's stock worth $160,000 after acquiring an additional 10,000 shares during the period.
Analyst Upgrades and Downgrades
NYXH has been the subject of a number of recent research reports. HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Nyxoah in a report on Tuesday, April 8th. Stifel Nicolaus cut their price target on shares of Nyxoah from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Monday, April 21st.
Read Our Latest Analysis on Nyxoah
Nyxoah Stock Performance
NASDAQ NYXH traded down $0.02 during trading hours on Thursday, reaching $7.72. 19,344 shares of the company were exchanged, compared to its average volume of 75,361. The stock has a market capitalization of $262.94 million, a P/E ratio of -3.62 and a beta of 1.65. The company has a quick ratio of 3.35, a current ratio of 3.59 and a debt-to-equity ratio of 0.22. Nyxoah has a 1 year low of $5.55 and a 1 year high of $11.87. The business's 50 day simple moving average is $6.84 and its 200-day simple moving average is $8.43.
Nyxoah (NASDAQ:NYXH - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.14). Nyxoah had a negative net margin of 1,571.39% and a negative return on equity of 63.37%. The firm had revenue of $1.12 million during the quarter, compared to analysts' expectations of $1.64 million. On average, equities research analysts expect that Nyxoah will post -1.91 earnings per share for the current year.
Nyxoah Company Profile
(
Get Free Report)
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
Read More
Before you consider Nyxoah, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nyxoah wasn't on the list.
While Nyxoah currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.